Double Major Ablation foriMammary Carcinoma
Ian Hutton FRCS (for Ian Burn FRcs) (Department ofSurgery, Hanunersmith Hospital and RoyalPostgraduate Medical School, London W12) Miss M W, aged 41. Secretary History: This patient underwent right simple mastectomy with postoperative radiotherapy for carcinoma of the breast in 1965 at the age of 33. She remained well for three years, but then developed persistentsevere low back pain. Routine hematological investigations were normal, but serum calcium and urinary calcium excretion were raised. Radiographs demonstrated metastases in spine, pelvis and left ribs. She was treated by an immediate pituitary ablation in July 1968, using 90Yttrium rods implanted through a transnasal cannula under radiological control.
Her progress following major endocrine ablation was satisfactory and her pain disappeared within one month of the procedure. She was maintained on routine cortisone replacement therapy and remained in excellent health, totally symptom free. There was radiographic evidence of healing of the skeletal deposits and she was regarded as having an excellent response to the endocrine therapy. She remained entirely free of symptoms for almost four years, until May 1972. She then noticed skin nodules on the trunk, and biopsy confirmed these to be malignant nodules, secondary to mammary cancer.
Assessment of pituitary function during the remission period was made by serial measurements of radioiodine (181) uptake at 48 hours by the thyroid gland. Preoperatively the value was 35.1 %, and it fell progressively to 15.3 % by June 1972. Thyroxine replacement therapy, however, was never necessary in this patient, for she remained clinically euthyroid. Because of the previous good response to pituitary ablation, and putative evidence of some remaining functioning pituitary tissue, as judged by her euthyroid state, further major endocrine ablation was considered. The cutaneous metastases continued to increase and there was evidence ofrecurrence of the skeletal metastases. Total surgical hypophysectomy by the transethmoidal route was therefore carried out on 8 November 1972. Her immediate postoperative progress was satisfactory, although by January 1973 there had been no tumour response. Histology of the excised tissue showed that some normal-looking pituitary cells were present with evidence of secretory activity.
Comment
Edelstyn et al. (1968) suggest that complete destruction of the pituitary is essential for a complete response, because surviving pituitary tissue can maintain tumour growth. They showed that 70% of patients had pituitary tissue left behind after transfrontal hypophysectomy, and that remission rates were greater when the hypophysectomy was complete. Roberts (1970), using growth hormone assays, found ablation to be complete in all patients who responded. However, although our patient had a good remission of four years, her pituitary ablation was clearly incomplete.
The other factors known to influence response to major ablation were varied in this patient: the interval between mastectomy and the appearance of skeletal metastases was relatively short and thus somewhat unfavourable, as was her age; her urinary discriminant was positive and thus favourable and, at the time of the pituitary ablation, disease appeared to be confined to the skeleton. The presence of some degree of calcium imbalance is generally regarded as unfavourable, however, in terms of subsequent response to endocrine therapy. The decision to carry out a second major ablation was a departure from conventional practice. It was made because of the suspicion of Mr Ian Burn said that about one-quarter of all patients with advanced mammary cancer responded favourably to major endocrine ablation. Recent clinical trials in this country had shown conclusively that immediate major ablation offered no advantage over a programme of simple endocrine therapy followed by major ablation when the simple therapy failed. It could now be recommended, therefore, that pituitary ablation should not be used in these patients until after a trial period of simple therapy, namely oophorectomy, cestrogens or androgens, according to the menopausal status.
Analgesic Nephropathy Associated with Paracetamol D R Master MB (for D M Krikler MD FRCP) (Prince of Wales's Hospital, London N15)
Mrs G C, aged 53 History: Vague intermittent epigastric pain, nausea and vomiting, tiredness and anorexia for two years. On specific questioning it was found that she had habitually taken paracetamol for at least ten years, averaging three tablets daily, for 'blinding headaches'. She only took other analgesics, usually tab. codeine co., when her supply of paracetamol ran out. Previously she had taken Veganin tablets for 2-3 years, but in rather smaller quantities. Total estimated phenacetin consumption since analgesic abuse began was less than 1 kg, compared with more than 5.5 kg of paracetamol.
Investigations: Hb 10.0 g/100 ml, blood urea 336 mg/100 ml, plasma CO2 8 mEq/l., creatinine clearance 4.5 ml/min. IVP demonstrated multiple small calcified areas in calyceal regions, some with translucent centres, indicating papillary necrosis. Withdrawal of analgesics and correction of electrolyte disturbances resulted in blood urea falling to 70 mg/100 ml and plasma CO2 rising to 29 mEq/l. over eight weeks.
Discussion
Analgesic nephropathy is most commonly attributed to phenacetin, usually when ingested as a constituent of a mixture. Aspirin alone has been blamed for papillary necrosis (Prescott 1969 ) but this is clearly exceptional. Paracetamol has been suspected because it is the active agent to which phenacetin is converted in the body. One case of pure paracetamol nephropathy has been reported (Krikler 1967) , and one further case has been provisionally classified as paracetamol nephropathy, although with reservations in view of the atypical feature of proteinuria (Kerr 1970) . In our case, analgesics containing phenacetin have been consumed, but this intake has been small compared with that of paracetamol. While paracetamol was clearly not the only substance consumed, it was the major analgesic used and may have played a primary role. While paracetamol is a widely used and generally safe mild analgesic, hepatic damage is increasingly recognized as a consequence of acute overdosage; renal damage is only rarely reported and appears to occur infrequently, but it seems prudent to bear this in mind as a possible consequence of paracetamol abuse. The fact that analgesics are often taken as mixtures, or that different substances are consumed from time to time, makes precise attribution of blame to a particular substance difficult. Dr B I Hoffbrand ( Whittington Hospital, London N19) said that as the patient had previously taken excessive amounts of analgesics containing phenacetin this might have contributed to the establishment of her renal disease. He asked whether steps had been taken to confirm her statements that she was no longer taking any unprescribed analgesic preparations, particularly ones containing phenacetin.
Dr D R Master said that whilst one could never be certain that the patient no longer took unprescribed analgesics, it appeared to be unlikely. She and her family were fully aware of the implications of further analgesic abuse.
Dr D M Krikler said that papillary necrosis appeared to develop because of the high concentration of paracetamol or other analgesic at this site due to tubular reabsorption of water.
It was interesting that many cases of analgesic nephropathy had been recognized in Sweden, Switzerland and Australia, and also that many people could take large amounts of analgesics without apparent ill effect; it was not known what other factors determined this. In this patient paracetamol was not the sole agent, but she had taken far more paracetamol than other substances, over a longer period, and it seemed to have played a major role. The whole question of analgesic nephropathy was constantly bedevilled by the multiplicity of drugs that were taken.
